ArticleFrontiers in pharmacology2022
Systematic evaluation of tumor microenvironment and construction of a machine learning model to predict prognosis and immunotherapy efficacy in triple-negative breast cancer based on data mining and sequencing validation.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Development of a machine learning-based risk prediction model and analysis of risk factors for docetaxel-induced bone marrow suppression in breast cancer patients.International journal of clinical pharmacy · 2025Article
- Neoadjuvant Immunotherapy in Hormone Receptor-Positive Breast Cancer: From Tumor Microenvironment Reprogramming to Combination Therapy Strategies.International journal of molecular sciences · 2025Review
- High expression of GRB14 is associated with cancer progression and poor prognosis in gastric cancer.Discover oncology · 2025Article
- TMB as a predictive biomarker for ICI response in TNBC: current evidence and future directions for augmented anti-tumor responses.Clinical and experimental medicine · 2025Review
- Innovative Approaches to EMT-Related Biomarker Identification in Breast Cancer: Multi-Omics and Machine Learning Methods.Biotech (Basel (Switzerland)) · 2025Review
- Revolutionizing breast cancer immunotherapy by integrating AI and nanotechnology approaches: review of current applications and future directions.Bioelectronic medicine · 2025Review
- Immune Cytolytic Activity and Strategies for Therapeutic Treatment.International journal of molecular sciences · 2024Review
- Innovations in Artificial Intelligence-Driven Breast Cancer Survival Prediction: A Narrative Review.Cancer informatics · 2024Article
- Improving efficacy of TNBC immunotherapy: based on analysis and subtyping of immune microenvironment.Frontiers in immunology · 2024Review
- Prediction and associated factors of non-steroidal anti-inflammatory drugs efficacy in migraine treatment.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.